Diabetes Complications: Clinical Trials

289 trials for Diabetes Complications, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

164 completed, 50 terminated, 40 unknown, 13 withdrawn. 289 Phase 3, 63 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3289Completed 164, Terminated 50, Unknown 40, Withdrawn 13, Recruiting 11, Not yet recruiting 7, Active not recruiting 4
Phase 263Completed 30, Unknown 14, Terminated 10, Withdrawn 4, Recruiting 3, Active not recruiting 1, Not yet recruiting 1

Follow Diabetes Complications: new trials by email Literature Review of Diabetes Complications trials Research Report on Diabetes Complications

Trials (filtered) newest first · largest first

All 289 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
OLN324, Aflibercept - Diabetic Macular Edema (DME)
Phase 3Not yet recruitingOllin Biosciences, Inc.4502026-10-152026-09-25
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)
OLN324, Aflibercept - Diabetic Macular Edema (DME)
Phase 3Not yet recruitingOllin Biosciences, Inc.4502026-10-152026-09-25
a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers
Standard of Care, BIOxHEAL (human amniotic membrane allograft) - Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft
Phase 3RecruitingApplied Biologics, LLC2532026-10-082026-10-16
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema
Phase 3RecruitingMerck Sharp & Dohme LLC11042026-09-252026-11-12
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy - Type 2 Diabetes Mellitus (T2DM)
Phase 3WithdrawnEurofarma Laboratorios S.A.2026-09-012025-12-18
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema
Phase 3RecruitingMerck Sharp & Dohme LLC9602026-08-272026-11-12
Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia
Experimental: Pregabalin XR, Comparator: Dorene Tabs, Comparator placebo - Diabetic Neuropathy, Neuropathic Pain
Phase 3RecruitingBrainfarma Industria Química e Farmacêutica S/A3482026-06-182026-07-20
Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease
Hua Yu Wan Capsule, Aspirin - Peripheral Arterial Disease, Diabetic Angiopathies
Phase 3Not yet recruitingXuanwu Hospital, Beijing3002026-06-012026-06-22
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Surabgene Lomparvovec, Sham, Topical Steroid - Diabetic Retinopathy
Phase 2 / Phase 3RecruitingAbbVie5762026-06-012026-10-29
"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
Dapagliflozin +Finerenone arm, Dapagliflozin arm - Diabetic Nephropathy
Phase 3Not yet recruitingChittagong Medical College882026-05-012026-05-20
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
Semaglutide, 1.34 mg/mL, Placebo - Foot Ulcer Due to Type 2 Diabetes Mellitus
Phase 3RecruitingOle Lander Svendsen522026-04-242026-05-12
Phase IIb and III Safety and Efficacy Study Chlorin E6 Gel Photodynamic Therapy for Diabetic Foot Ulcers:
Chlorin E6 Gel - Diabetic Foot Ulcer (DFU)
Phase 3RecruitingUnited Medical and Dental College3002026-04-022026-04-07
The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy
DLBS1033, Placebo Comparator: Placebo + Standard Therapy - Diabetic Polyneuropathy, Peripheral Nervous System Diseases
Phase 2 / Phase 3Not yet recruitingUniversitas Sebelas Maret342026-03-012026-03-16
Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
Amniotic Tissue Allograft - Chronic Wounds, Venous Leg Ulcers (VLUs)
Phase 3Not yet recruitingBardia Anvar6002026-01-012025-11-06
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
Reamberin, Placebo - Diabetic Ketoacidosis
Phase 2 / Phase 3RecruitingPOLYSAN Scientific & Technological Pharmaceutical Company3122025-05-012025-06-24
The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcers
Bromelain, Placebo - Diabetic Foot Ulcer (DFU)
Phase 3Not yet recruitingDr Azita Hekmatdoost702025-03-012025-01-22
Tailored Exercise Training Study Among Adults With HFpEF
Moderate-intensity continuous training (MCT), Resistance training, Weight loss - HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Phase 2 / Phase 3RecruitingUniversity of Texas Southwestern Medical Center1202025-02-182025-10-31
SGLT2 Adjunct in T1D
Empagliflozin (EMPA), Placebo - Type 1 Diabetes, Nephropathy, Diabetic
Phase 2 / Phase 3CompletedAin Shams University862024-11-202026-05-18
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Sotagliflozin, Placebo - Diabetic Nephropathies, Kidney Failure, Chronic
Phase 3RecruitingAlessandro Doria1502024-10-312026-03-24
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
Xianglei Tangzu Gao, Vehicle Cream - Diabetic Foot Ulcer
Phase 2 / Phase 3Active not recruitingOneness Biotech Co., Ltd.1202024-08-162026-06-12

Showing 20 of 289. Sign in to see all of them.

Narrower conditions

Diabetic Neuropathies (76)  ·  Diabetic Foot (73)  ·  Diabetic Retinopathy (70)  ·  Diabetes Mellitus (57)  ·  Diabetic Nephropathies (55)  ·  Diabetes Mellitus, Type 2 (27)  ·  Macular Edema (17)  ·  Pain (16)  ·  Neuralgia (13)  ·  Diabetes Mellitus, Type 1 (11)  ·  Kidney Diseases (11)  ·  Peripheral Nervous System Diseases (11)  ·  Ulcer (10)  ·  Hypoglycemia (9)

Broader conditions

Endocrine System Diseases (289)  ·  Diabetes Mellitus (232)  ·  Cardiovascular Diseases (152)  ·  Vascular Diseases (150)  ·  Diabetic Angiopathies (142)  ·  Nutritional and Metabolic Diseases (97)  ·  Metabolic Diseases (96)  ·  Glucose Metabolism Disorders (93)  ·  Nervous System Diseases (88)  ·  Pathological Conditions, Signs and Symptoms (79)  ·  Neuromuscular Diseases (76)  ·  Skin Diseases (73)  ·  Skin and Connective Tissue Diseases (73)  ·  Leg Ulcer (72)

Interventions

Standard of Care (14)  ·  aflibercept (12)  ·  Insulin Aspart (10)  ·  Pregabalin (10)  ·  Ranibizumab (10)  ·  Bevacizumab (9)  ·  salicylhydroxamic acid (7)  ·  Duloxetine Hydrochloride (6)  ·  Insulin, Regular, Human (6)  ·  2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)- (5)  ·  Triamcinolone Acetonide (5)  ·  Fenofibrate (4)  ·  Lacosamide (4)  ·  Microspheres (4)  ·  Octreotide (4)

Sponsors

Florida Atlantic University (10)  ·  Eli Lilly and Company (8)  ·  UCB Pharma (7)  ·  Jaeb Center for Health Research (6)  ·  National Eye Institute (NEI) (6)  ·  Novartis Pharmaceuticals (6)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (6)  ·  Pfizer (5)  ·  Bayer (4)  ·  Chromaderm, Inc. (4)  ·  Helixmith Co., Ltd. (4)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4)  ·  Kodiak Sciences Inc (4)  ·  Tanta University (4)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (4)

Countries

United States (110)  ·  Germany (35)  ·  Canada (30)  ·  Spain (27)  ·  United Kingdom (27)  ·  Italy (22)  ·  Australia (20)  ·  Poland (20)  ·  China (18)  ·  France (18)  ·  Denmark (17)  ·  Hungary (17)  ·  Mexico (17)  ·  Netherlands (16)  ·  Puerto Rico (16)

Top investigators

Betty Tuller, PhD (6)  ·  Pablo Velazquez-Martin, MD (4)  ·  Betty Tuller, Ph.D (3)  ·  Karl Beutner (3)  ·  Hugo Quiroz-Mercado, MD (2)  ·  Jean-Charles Kerihuel, MD (2)  ·  Lisa R Grillone, PhD (2)

Results publications

PMID 33107592, PMID 37872654, PMID 40526444, PMID 18441312, PMID 18990064, PMID 20008710, PMID 20427088, PMID 21571677, PMID 22999634, PMID 25018648, PMID 25439614, PMID 26802783, PMID 27611736, PMID 30084288, PMID 30206821, PMID 30521533, PMID 31802967, PMID 33280027, PMID 33358451, PMID 36251465, PMID 36287567, PMID 36328655, PMID 36639130, PMID 36864892, PMID 36927680, PMID 37745646, PMID 38046911, PMID 38048573, PMID 38508632, PMID 38682786, PMID 38770818, PMID 39380152, PMID 40315020, PMID 40892478, PMID 41196655, PMID 41198855, PMID 41289823, PMID 41533467, PMID 41679125, PMID 41827014, PMID 42234437, PMID 11128345, PMID 12766097, PMID 15504999, PMID 15834546, PMID 17065669, PMID 17257476, PMID 17327325, PMID 17327338, PMID 17563333

NIH funding

2015 (4), U10EY014231 (3), 2004 (2), 2005 (2), 2009 (2), U10EY014229 (2), U10EY018817 (2), 1KL2RR025015-01 (1), 2014 (1), 2017 (1), 2019 (1), 2023 (1), N01HC095178 (1), P30DK017047 (1), R01DK047112 (1)